Unmasking Ehlers-Danlos Syndrome Through Reduction Mammaplasty: An Illustrative Case and a Systematic Literature Review
Abstract
Ehlers-Danlos syndrome (EDS) is characterized by joint hypermobility, skin hyperextensibility, and tissue fragility, which may worsen symptomatic macromastia. Concerns about elevated surgical risk have historically discouraged elective procedures in EDS patients; however, postoperative complications may themselves prompt an EDS diagnosis, as illustrated by our case. This relationship prompted the conduct of a systematic review examining outcomes of reduction mammaplasty in EDS. A 37-year-old woman underwent bilateral inferior pedicle reduction mammaplasty for symptomatic mammary hyperplasia. Persistent intraoperative oozing resulted in postoperative anemia (hemoglobin decline from 13.3 g/dL to 10.4 g/dL). Additional complications included delayed wound healing, hypertrophic scarring, and transient left upper extremity weakness. Hematologic evaluation was unremarkable. Clinical assessment revealed joint hypermobility (Beighton score ≥5/9), positive Walker and Steinberg signs, skin hyperextensibility, easy bruising, and menorrhagia, leading to a clinical diagnosis of hypermobile EDS. A systematic review of PubMed, Scopus, and Google Scholar (December 1950 to June 2025) was performed and included all study designs. Extracted data included demographics, interventions, complications, revision rates, and satisfaction. Two independent reviewers assessed quality using Joanna Briggs Institute (JBI) critical appraisal tools. Of the 115 identified records, the following four studies…
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.